HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Neutral 52.2%

Neg 0% Neu 52.2% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $20 to $15.